AbbVie's Tavapadon (Juvmo) Pill Wins FDA Approval for Parkinson's Disease
- FDA approved AbbVie's Juvmo (tavapadon), a once-daily oral pill for Parkinson's disease, usable alone early on or alongside levodopa for motor fluctuations.
- It's the first selective D1/D5 dopamine receptor partial agonist approved for Parkinson's, a mechanism distinct from older D2/D3 agonists, aimed at controlling motor symptoms with fewer impulse-control or sleep-attack risks.
- AbbVie gained tavapadon via its 2023 Cerevel Therapeutics acquisition; US launch is planned October 2026.
💡 Points
This is AbbVie's first tangible payoff from the $8.7B Cerevel bet — proof the deal wasn't just pipeline padding. But novelty alone won't move share: Parkinson's prescribing is sticky, generics dominate, and neurologists switch stable patients reluctantly. The cleaner side-effect profile is a real wedge, yet formulary inertia will decide if it's more than a niche add-on.